Guardant Health vs Illumina Which Is More Attractive?

Guardant Health and Illumina are two leading companies in the genomics and diagnostics industry, with both offering cutting-edge technologies for genetic testing and personalized medicine. Guardant Health specializes in liquid biopsy tests for cancer detection and monitoring, while Illumina is a market leader in DNA sequencing and analysis. Investors are closely watching the performance of both stocks as they navigate the rapidly evolving healthcare landscape and potential for groundbreaking advancements in precision medicine.

Guardant Health or Illumina?

When comparing Guardant Health and Illumina, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Guardant Health and Illumina.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Guardant Health has a dividend yield of -%, while Illumina has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Guardant Health reports a 5-year dividend growth of 0.00% year and a payout ratio of -4.14%. On the other hand, Illumina reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Guardant Health P/E ratio at -7.14 and Illumina's P/E ratio at -14.81. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Guardant Health P/B ratio is -60.87 while Illumina's P/B ratio is 9.63.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Guardant Health has seen a 5-year revenue growth of 0.69%, while Illumina's is 0.26%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Guardant Health's ROE at -1240.25% and Illumina's ROE at -41.29%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $29.09 for Guardant Health and $146.07 for Illumina. Over the past year, Guardant Health's prices ranged from $15.81 to $37.04, with a yearly change of 134.28%. Illumina's prices fluctuated between $90.17 and $156.66, with a yearly change of 73.75%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.